Trial site
Clayton
Clayton, Victoria 3168, AustraliaNot linked to an institution yet
- 17running trials
- 6closed trials
The trials here
What the 23 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 28 trials
- Phase 1/23 trials
- Phase 41 trial
- Status
- Active, not recruiting13 trials
- Completed4 trials
- Recruiting4 trials
- Terminated2 trials
- Lead sponsor
- Novartis Pharmaceuticals23 trials
Running trials
Recruiting
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
NCT07564401· Phase 1/2· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
NCT07102628· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT06991556· Phase 2· Novartis Pharmaceuticals· Source
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148· Phase 1/2· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
NCT06581198· Phase 2· Novartis Pharmaceuticals· Source
Active, not recruiting
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941· Phase 2· Novartis Pharmaceuticals· Source
Active, not recruiting
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
NCT05888493· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)
NCT06254482· Phase 2· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
NCT05201066· Phase 2· Novartis Pharmaceuticals· Source
Active, not recruiting
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
NCT05653349· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Atrasentan in Patients With Proteinuric Glomerular Diseases
NCT04573920· Phase 2· Novartis Pharmaceuticals· Source
Active, not recruiting
CINC424A2X01B Rollover Protocol
NCT02386800· Phase 4· Novartis Pharmaceuticals· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error